A mass drug administration program to protect people from LF has been underway since 2004 under the flagship campaign 'Hathipaon Mukt Bharat'. The aim of the program is to deliver preventive medicines to high-risk communities with specific focus on the four most endemic states: Uttar Pradesh, Bihar, West Bengal and Jharkhand. The goal of MDA is to reduce the density of parasites circulating in the blood of infected persons and the intensity of infection in communities to levels where transmission is no longer sustainable by the mosquito vector.
Amar, a farmer was left partially disabled when he was diagnosed with Lymphatic filariasis 25 years ago. "I have eight children who now take care of me but we faced economic hardships", he said. Despite both Amar and his wife suffering from LF, awareness is low. Amar says, "none of my children take the medicines because we thought only those suffering should take the drugs. People in our village don't even know it is caused by mosquitoes". The last round of MDA in Uttar Pradesh took place on February 10-12 in 20 districts that included Gorakhpur, Khushinagar and Barabanki. The next round is scheduled for March 19-21 for seven districts.
In Bihar, Madan Singh copes with erratic fever due to Lymphatic filariasis and it grateful to the ASHA workers who create awareness in the community. "There is no stigma attached to this but a lot more awareness is required to control the situation. ASHA worker do their bit but it requires more if we want to end the disease", he said.
The worm blocks the lymphatic system which causes swelling in the legs, arms and other part of the body, making them look large puffy and elephant-like. Although filariasis does not kill, it causes lifelong disability and imposes severe social and economic burdens on the affected individuals and their families. The disease is spread by a parasitic worm and is transmitted among people by mosquito bites.
Follow NDTV for latest election news and live coverage of assembly elections 2019 in Maharashtra and Haryana.
Subscribe to our YouTube channel, like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.